A Phase-2 Study of Nivolumab and Ipilimumab Combination, Ipilimumab alone or Cabazitaxel in Men with metastatic, castration-resistant Prostate Cancer (Check Mate-650) - AP 110/20 of AUO Second/Third-Line Therapy after Failure of Docetaxel in Patients with metastatic Prostate Cancer (mCRPC )

被引：0
|
作者：
Rexer, Heidrun [1 ]
Grimm, Marc-Oliver [2 ]
Boegemann, Martin [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Univ Klinikum Jena, Klin & Poliklin Urol, Leiter Klin Prufung, Klinikum 1, D-07747 Jena, Germany
[3] Deutsch Krebsgesell eV, Organgrp Sprecher Arbeitsgemeinschaft Urol, Kuno Fischer Str 8, D-14057 Berlin, Germany
来源：
AKTUELLE UROLOGIE | 2021年 / 52卷 / 04期
关键词：
D O I：
10.1055/a-1469-0239
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：316 / 317
页数：2
相关论文
共 50 条
  • [11] Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
    Meulenbeld, Hielke J.
    Bleuse, Jean P.
    Vinci, Elio M.
    Raymond, Eric
    Vitali, Giordano
    Santoro, Armando
    Dogliotti, Luigi
    Berardi, Rossana
    Cappuzzo, Federico
    Tagawa, Scott T.
    Sternberg, Cora N.
    Jannuzzo, Maria G.
    Mariani, Mariangela
    Petroccione, Anna
    de Wit, Ronald
    BJU INTERNATIONAL, 2013, 111 (01) : 44 - 52
  • [12] Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
    Sharma, Padmanee
    Krainer, Michael
    Saad, Fred
    Castellano, Daniel
    Bedke, Jens
    Kwiatkowski, Mariusz
    Patnaik, Akash
    Procopio, Giuseppe
    Wiechno, Pawel
    Kochuparambil, Samith Thomas
    Thomas, Christian
    Arija, Jose Angel Arranz
    McCune, Steven L.
    Hansen, Steinbjorn
    Daugaard, Gedske
    Amin, Neha P.
    Wang, Yumeng
    David, Justin M.
    Pachynski, Russell Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [13] Second-/Third-Line Therapy after Failure of Next-Generation-Hormone Therapy (NHA) and possibly Second-Line Therapy with Abiraterone for Patients with metastatic Prostate Cancer (mCRPC) Randomized, double-blind Phase-III Study of Pembrolizumab (MK-3475) and plus Enzalutamide Combination versus Placebo and Enzalutamide Combination in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) (KEYNOTE-641) AP 107/19 of the AUO
    Rexer, H.
    Stenzl, A.
    Boegemann, M.
    AKTUELLE UROLOGIE, 2021, 52 (03) : 218 - 219
  • [14] A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.
    Buonerba, Carlo
    Grillone, Francesco
    Rossetti, Sabrina
    Livi, Lorenzo
    Scartozzi, Mario
    Tagliaferri, Pierosandro
    Bruzzese, Dario
    Scafuri, Luca
    Riccio, Vittorio
    Costabile, Ferdinando
    Bosso, Davide
    Iaccarino, Simona
    Facchini, Gaetano
    Carrano, Simone
    Izzo, Michela
    Caraglia, Michele
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [15] Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial
    Shenderov, Eugene
    Boudadi, Karim
    Fu, Wei
    Wang, Hao
    Sullivan, Rana
    Jordan, Alice
    Dowling, Donna
    Harb, Rana
    Schonhoft, Joseph
    Jendrisak, Adam
    Carducci, Michael A.
    Eisenberger, Mario A.
    Eshleman, James R.
    Luo, Jun
    Drake, Charles G.
    Pardoll, Drew M.
    Antonarakis, Emmanuel S.
    PROSTATE, 2021, 81 (06): : 326 - 338
  • [16] A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D)
    Eigl, B. J.
    Trudeau, M. G.
    Winquist, E.
    Chi, K. N.
    Eliasziw, M.
    North, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [17] Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life.
    Mansueto, Giovanni
    De Tursi, Michele
    Ratta, Raffaele
    Fabbri, Maria Agnese
    Quadrini, Silvia
    Salesi, Nello
    Rozzi, Antonio
    Sperduti, Isabella
    Ciancola, Fabrizio
    Gamucci, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [18] Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Slovin, S. F.
    Higano, C. S.
    Hamid, O.
    Tejwani, S.
    Harzstark, A.
    Alumkal, J. J.
    Scher, H. I.
    Chin, K.
    Gagnier, P.
    McHenry, M. B.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1813 - 1821
  • [19] An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
    Fizazi, Karim
    Drake, Charles G.
    Shaffer, David R.
    Pachynski, Russell
    Saad, Fred
    Ciprotti, Marika
    Kong, George
    Ryan, Charles J.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [20] A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE
    Buonerba, C.
    Bosso, D.
    De Placido, S.
    Di Lorenzo, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345